Log In
Print this Print this

PLK1 UsiRNA formulated in a DiLA2 lipid-based delivery vehicle

  Manage Alerts
Collapse Summary General Information
Company Marina Biotech Inc.
DescriptionDuplex short interfering RNAs (siRNAs) modified with unlocked nucleobase analogs (UNA) formulated in a DiLA2 liposome formulation targeting polo-like kinase 1 (PLK1)
Molecular Target Polo-like kinase 1 (PLK1) (STPK13)
Mechanism of ActionGene silencing
Therapeutic ModalityNucleic acid: Linear RNA: siRNA

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments





 Deals Details
Get a free BioCentury trial today